Kailera, a portfolio company of RTW Biotech Opportunities (RTW), has announced positive topline data from the 8 mg dose of Hengrui Pharmaceutical’s Phase 2 clinical trial (HRS9531-203) of HRS9531, a GLP-1/GIP receptor dual agonist, in individuals living with obesity or overweight. The clinical trial results showed that a once-weekly subcutaneous injection of the 8 mg … Continue reading RTW Biotech Opportunities’ Kailera announces positive data in phase 2 obesity trial